Keyphrases
Inflammatory Bowel Disease
100%
Infliximab
100%
Clinical Response
28%
Remission
28%
Second Dose
28%
Stenosis
14%
Third Dose
14%
Ulcerative Colitis
14%
Response to Treatment
14%
Combined Treatment
14%
Biological Therapy
14%
Endoscopic Response
14%
Herpes Zoster
14%
Year of Diagnosis
14%
Imaging Response
14%
Treatment Discontinuation
14%
Immunosuppressive Medication
14%
Refractory Disease
14%
Historical Cohort
14%
Pyoderma Gangrenosum
14%
Extraintestinal Symptoms
14%
Sinusitis
14%
Economic Cost
14%
Patient-initiated
14%
Medicine and Dentistry
Inflammatory Bowel Disease
100%
Infliximab
100%
Side Effect
42%
Patient with Inflammatory Bowel Disease
42%
Disease
28%
Drug Therapy
14%
Health Care Cost
14%
Immunosuppressive Drug
14%
Biological Therapy
14%
Ulcerative Colitis
14%
Physician
14%
Disseminated Herpes Zoster
14%
Sinusitis
14%
Stenosis
14%
Pyoderma gangrenosum
14%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Infliximab
100%
Side Effect
42%
Disease
28%
Remission
28%
Immunosuppressive Agent
14%
Ulcerative Colitis
14%
Sinusitis
14%
Herpes Zoster
14%
Pyoderma gangrenosum
14%
Stenosis
14%
Immunology and Microbiology
Inflammatory Bowel Disease
100%
Infliximab
100%
Immunosuppressive Drug
14%
Ulcerative Colitis
14%
Sinusitis
14%
Herpes Zoster
14%